Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: Novel post-transcriptional, post-translational regulation

Clinical and Experimental Metastasis

Volumn 22, Issue 8, 2005, Pages 663-673

  Khan, Subarna A ^a   Cook, Amy C ^c   Kappil, Maya ^a   Günthert, Ursula ^d   Chambers, Ann F ^c,e   Tuck, Alan B ^c,e,f   Denhardt, David T ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d UNIVERSITY OF BASEL   (Switzerland)

^e LONDON REGIONAL CANCER PROGRAM   (Canada)

^f LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Breast cancer; CD44 variant; Cell migration; Osteopontin

Indexed keywords

CD44V10 ANTIGEN; CD44V6 ANTIGEN; CD44V8 ANTIGEN; CD44V9 ANTIGEN; HERMES ANTIGEN; ISOPROTEIN; MESSENGER RNA; OSTEOPONTIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; CULTURE MEDIUM; CYTOMEGALOVIRUS; HUMAN; HUMAN CELL; METASTASIS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; VALIDATION PROCESS;

ANTIGENS, CD44; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MEMBRANE; CELL MOVEMENT; DNA PRIMERS; FLOW CYTOMETRY; HUMANS; NEOPLASM METASTASIS; OSTEOPONTIN; PROTEIN PROCESSING, POST-TRANSLATIONAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, MESSENGER; SIALOGLYCOPROTEINS;

EID: 33747469572     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10585-006-9007-0     Document Type: Article

References (48)

1. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS (2001) Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 107:1055-1061
2. Chabas D, Baranzini SE, Mitchell D et al (2001) The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294:1731-1735
3. Weber GF (2001) The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 1552:61-85
4. Yeatman TJ, Chambers AF (2003) Osteopontin and colon cancer progression. Clin Exp Metastasis 20:85-90
5. Furger KA, Menon RK, Tuck AB et al (2001) The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1:621-632
6. Rittling SR, Chambers AF (2004) Role of osteopontin in tumour progression. Br J Cancer 90:1877-1881
7. Sodek J, Ganss B, McKee MD (2000) Osteopontin. Crit Rev Oral Biol Med 11:279-303
8. Denhardt DT, Giachelli CM, Rittling SR (2001) Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol 41:723-749
9. Al-Shami R, Sörensen ES, Ek-Rylander B et al (2005) Phosphorylated osteopontin promotes migration of human choriocarcinoma cells via a p70 S6 kinase-dependent pathway. J Cell Biochem 94:1218-1233
10. Weber GF, Ashkar S, Cantor H (1997) Interaction between CD44 and osteopontin as a potential basis for metastasis formation. Proc Assoc Am Phys 109:1-9
11. Günthert U (1993) CD44: a multitude of isoforms with diverse functions. Curr Top Microbiol Immunol 184:47-63
12. Naor D, Nedvetzki S, Golan I et al (2002) CD44 in cancer. Crit Rev Clin Lab Sci 39:527-579
13. Ponta H, Sherman L, Herrlich PA (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4:33-45
14. Cichy J, Pure E (2003) The liberation of CD44. J Cell Biol 161:839-843
15. Murai T, Miyazaki Y, Nishinakamura H et al (2004) Engagement of CD44 promotes Rac activation and CD44 cleavage during tumor cell migration. J Biol Chem 279:4541-4550
16. Chellaiah MA, Biswas RS, Rittling SR et al (2003) Rho-dependent Rho kinase activation increases CD44 surface expression and bone resorption in osteoclasts. J Biol Chem 278:29086-29097
17. Zhu B, Suzuki K, Goldberg HA et al (2004) Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin. J Cell Physiol 198:155-167
18. Günthert U (1996) CD44 in malignant disorders. Curr Top Microbiol Immunol 213(Pt 1):271-285
19. Weber GF, Ashkar S, Glimcher MJ, Cantor H (1996) Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 271:509-512
20. Smith LL, Greenfield BW, Aruffo A, Giachelli CM (1999) CD44 is not an adhesive receptor for osteopontin. J Cell Biochem 73:20-30
21. Katagiri YU, Sleeman J, Fujii H et al (1999) CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res 59:219-226
22. Ue T, Yokozaki H, Kitadai Y et al (1998) Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 79:127-132
23. Tuck AB, Arsenault DM, O'Malley FP et al (1999) Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 18:4237-4246
24. Tuck AB, Elliott BE, Hota C et al (2000) Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem 78:465-475
25. Tuck AB, Hota C, Chambers AF (2001) Osteopontin(OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Res Treat 70:197-204
26. Cook AC, Tuck AB, McCarthy S et al (2005) Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression. Mol Carcinog 43:225-236
27. Mackay CR, Terpe HJ, Stauder R et al (1994) Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 124:71-82
28. Picker LJ, De los Toyos J, Telen MJ et al (1989) Monoclonal antibodies against the CD44 [In(Lu)-related p80], and Pgp-1 antigens in man recognize the Hermes class of lymphocyte homing receptors. J Immunol 142:2046-2051
29. Zheng Z, Katoh S, He Q et al (1995) Monoclonal antibodies to CD44 and their influence on hyaluronan recognition. J Cell Biol 130:485-495
30. Khan SA (2004) Regulation of CD44 and apoptosis-related gene Bcl-XL expression by osteopontin. Doctoral Dissertation, Rutgers University
31. Chellaiah MA, Kizer N, Biswas R et al (2003) Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol Biol Cell 14:173-189
32. Gao C, Guo H, Downey L et al (2003) Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells. Carcinogenesis 24:1871-1878
33. Marroquin CE, Downey L, Guo H, Kuo PC (2004) Osteopontin increases CD44 expression and cell adhesion in RAW 264.7 murine leukemia cells. Immunol Lett 95:109-112
34. Turley EA, Noble PW, Bourguignon LY (2002) Signaling properties of hyaluronan receptors. J Biol Chem 277:4589-4592
35. Thorne RF, Legg JW, Isacke CM (2004) The role of the CD44 transmembrane and cytoplasmic domains in coordinating adhesive and signalling events. J Cell Sci 117:373-380
36. Hsia DA, Lim ST, Bernard-Trifilo JA et al (2005) Integrin alpha4beta1 promotes focal adhesion kinase-independent cell motility via alpha4 cytoplasmic domain-specific activation of c-Src. Mol Cell Biol 25:9700-9712
37. Kayastha S, Freedman AN, Piver MS et al (1999) Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival. Clin Cancer Res 5:1073-1076
38. Tuck AB, O'Malley FP, Singhal H et al (1998) Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 79:502-508
39. Rudland PS, Platt-Higgins A, El-Tanani M et al (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62:3417-3427
40. Thalmann GN, Sikes RA, Devoll RE et al (1999) Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 5:2271-2277
41. Iczkowski KA, Bai S, Pantazis CG (2003) Prostate cancer overexpresses CD44 variants 7-9 at the messenger RNA and protein level. Anticancer Res 23:3129-3140
42. Irby RB, McCarthy SM, Yeatman TJ (2004) Osteopontin regulates multiple functions contributing to human colon cancer development and progression. Clin Exp Metastasis 21:515-523
43. Furger KA, Allan AL, Wilson SM et al (2003) Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res 1:810-819
44. Orian-Rousseau V, Chen L, Sleeman JP et al (2002) CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 16:3074-3086
45. Culty M, Shizari M, Thompson EW, Underhill CB (1994) Binding and degradation of hyaluronan by human breast cancer cell lines expressing different forms of CD44: correlation with invasive potential. J Cell Physiol 160:275-286
46. Van Driel M, Günthert U, van Kessel AC et al (2002) CD44 variant isoforms are involved in plasma cell adhesion to bone marrow stromal cells. Leukemia 16:135-143
47. Standal T, Borset M, Sundan A (2004) Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 26:179-184
48. Nilsson SK, Johnston HM, Whitty GA et al (2005) Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 106:1232-1239